S-1/顺铂对比5-FU/顺铂治疗初治弥漫型胃癌的III期试验
这项国际III期试验将361例初治弥漫型胃或胃食管结合部腺癌患者按2:1随机分配至S-1/顺铂组(n=239)或5-FU/顺铂组(n=122),主要终点总生存期两组无差异(中位OS 7.5 vs 6.6个月,HR 0.99,P=0.9312),客观缓解率S-1/顺铂组显著更高(34.7% vs 19.8%,P=0.01),安全性和疗效总体相似,主要终点未达到。
要点
- S-1/顺铂与5-FU/顺铂在初治弥漫型胃/胃食管结合部腺癌中疗效相似,主要终点OS无差异。
- S-1/顺铂组客观缓解率显著更高(34.7% vs 19.8%,P=0.01)。
- 两组安全性相似,S-1/顺铂组≥3/4级TEAE或导致停药的不良事件患者更少。
核心结论
- S-1/顺铂与5-FU/顺铂在初治晚期弥漫型胃或胃食管结合部腺癌患者中疗效和安全性相似,主要终点未达到。
研究设计与样本
- 国际III期随机试验,纳入初治、可测量、经中心病理确认的晚期弥漫型腺癌且体能状态0-1的患者,按2:1随机分配至S-1/顺铂组(n=239)或5-FU/顺铂组(n=122),共361例。
主要发现
- 中位OS S-1/顺铂组7.5个月(95%CI 6.7-9.3)vs 5-FU/顺铂组6.6个月(95%CI 5.7-8.1),HR 0.99(95%CI 0.76-1.28),P=0.9312。
- 客观缓解率S-1/顺铂组34.7% vs 5-FU/顺铂组19.8%,P=0.01。
- 无进展生存期和治疗失败时间两组无差异。
- 安全性两组相似,但S-1/顺铂组发生≥1个≥3/4级治疗中出现的不良事件或≥1个导致治疗中断的不良事件的患者少于5-FU/顺铂组。
- 每组各发生1例治疗相关死亡。
关键数值与推荐
- 每例患者中位治疗周期数两组均为4(范围:S-1/顺铂组1-20;5-FU/顺铂组1-30),剂量强度>95%。
临床怎么用
- 对于初治晚期弥漫型胃或胃食管结合部腺癌患者,S-1/顺铂与5-FU/顺铂疗效和安全性相似,可作为治疗选择。
局限性
- 原文明确因入组缓慢导致试验提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effect of histology-based treatment regimen on diffuse gastric adenocarcinoma has not been evaluated in clinical trials. This international phase III trial evaluated the efficacy and safety of S-1 (a contemporary oral fluoropyrimidine)/cisplatin versus 5-fluorouracil (5-FU)/cisplatin in chemotherapy-naïve patients with diffuse-type adenocarcinoma involving the gastroesophageal junction or stomach. PATIENTS AND METHODS: Eligibility criteria included untreated, measurable, advanced diffuse adenocarcinoma confirmed by central pathology and performance status of 0-1. Patients were randomized (2 : 1) to receive S-1/cisplatin or 5-FU/cisplatin. Primary end point was overall survival (OS), and secondary end points were progression-free survival, time to treatment failure, overall response rate, and safety. A multivariable analysis was also carried out. RESULTS: Overall, 361 patients were randomized (S-1/cisplatin, n = 239; 5-FU/cisplatin, n = 122); half (51%) were men, and median age was 56.0 years. In each group, median number of treatment cycles per patient was 4 (range, S-1/cisplatin: 1-20; 5-FU/cisplatin: 1-30), and dose intensity was >95%. OS was not different in the two groups {median OS with S-1/cisplatin, 7.5 [95% confidence interval (CI): 6.7, 9.3]; 5-FU/cisplatin, 6.6 [95% CI: 5.7, 8.1] months; hazard ratio, 0.99 [95% CI: 0.76, 1.28]; P = 0.9312}. Overall response rate was significantly higher in the S-1/cisplatin than 5-FU/cisplatin group (34.7% versus 19.8%; P = 0.01), but progression-free survival and time to treatment failure were not different. Safety was similar between the 2 groups; however, fewer patients treated with S-1/cisplatin than 5-FU/cisplatin had ≥1 grade 3/4 treatment-emergent adverse event or ≥1 adverse event resulting in treatment discontinuation. One treatment-related death occurred in each group. Slow accrual led to early termination. CONCLUSIONS: These data suggest that S-1/cisplatin and 5-FU/cisplatin are similar in efficacy and safety in untreated patients with advanced diffuse adenocarcinoma of the gastroesophageal junction or stomach. The primary end point was not met. CLINICALTRIAL.GOV REGISTRATION NUMBER: NCT01285557.
引用
- Ajani JA, Abramov M, Bondarenko I, et al. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017. PMID: 28911091. doi:10.1093/annonc/mdx275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。